Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32573433.
- Also identified by DOI 10.7554/eLife.57877 and PMC identifier 7311167.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
We review aspects of the antibody response to SARS-CoV-2, the causative agent of the COVID-19 pandemic. The topics we cover are relevant to immunotherapy with plasma from recovered patients, monoclonal antibodies against the viral S-protein, and soluble forms of the receptor for the virus, angiotensin converting enzyme 2. The development of vaccines against SARS-CoV-2, an essential public health tool, will also be informed by an understanding of the antibody response in infected patients. Although virus-neutralizing antibodies are likely to protect, antibodies could potentially trigger immunopathogenic events in SARS-CoV-2-infected patients or enhance infection. An awareness of these possibilities may benefit clinicians and the developers of antibody-based therapies and vaccines.
Medical subject headings
- Coronavirus Infections
- Immunization, Passive
- Pneumonia, Viral